Health & Medicine Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio AcquisitionBy adminSeptember 18, 20250 There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio…
